Actively Recruiting
Study of Gecacitinib for Safety and Effectiveness in Adults With Moderate-to-Severe Chronic Graft-versus-Host Disease After Two or More Prior Treatments
Led by Yujun DONG · Updated on 2025-06-10
24
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Chronic Graft-versus-Host Disease cGVHD is a frequent complication after allogeneic hematopoietic stem cell transplantation and a major cause of non-relapse death. This trial studies the safety, tolerability, and feasibility of gecacitinib, a new inhibitor targeting JAK and ACVR1 pathways, in patients with moderate-to-severe cGVHD who have already received two or more prior treatments. The study is conducted in phases 1 and 2 to evaluate this treatment approach in 24 participants. Participants will take oral gecacitinib hydrochloride tablets starting at 50 mg once daily on an empty stomach. The dose can be adjusted between 50 mg every other day and up to 100 mg twice daily based on tolerance and response. The initial treatment duration is at least 24 weeks, with patients showing disease stability allowed to continue treatment up to week 60 unless intolerance, disease progression, or new systemic therapy occurs first. Throughout the study, participants will have their response measured by overall response rate at week 24, as well as other assessments including symptom changes, survival without treatment failure, and quality of life scores over an average of 24 months. Safety monitoring includes tracking adverse events and drug reactions up to 28 days after the last dose. The study involves regular clinical evaluations to assess disease status and treatment effects.
CONDITIONS
Brief Title
Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here